Previously, Gourni et al. presented the first data on the new 68Ga-labeled high-affinity CXCR4 ligand 68Ga-CPCR4-2 (cyclo(D-Tyr(1)-[NMe]-D-Orn(2)-[4-(aminomethyl) benzoic acid), which is characterized by high in vivo stability and distinct and specific tumor accumulation [21]. This evidence concerns the gene CXCR4 and neoplasm.